Armistice Capital, LLC Reports 5.94% Stake in Autolus Therapeutics plc (AUTL)

Armistice Capital, LLC and its managing member, Steven Boyd, filed a Schedule 13G/A on May 15, 2026, reporting a 5.94% stake in Autolus Therapeutics plc (AUTL). The reporting persons disclosed beneficial ownership of 15,800,000 American Depositary Shares as of March 31, 2026. This position represents an increase from a previously reported 0.0% ownership, indicating a significant new accumulation of shares. Armistice Capital, LLC serves as the investment manager for the Armistice Capital Master Fund Ltd., which is the direct holder of the shares. Under the investment management agreement, Armistice Capital exercises shared voting and shared dispositive power over the securities. Steven Boyd, in his capacity as managing member of Armistice Capital, may also be deemed to beneficially own these shares. The filing indicates that the securities were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. The total value of the holdings is estimated at approximately $25.75 million based on the filing date data.